Radiothérapie prostatique : prédiction de la toxicité tardive à partir des données dosimétriques
暂无分享,去创建一个
[1] P. Maingon,et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. , 2004, International journal of radiation oncology, biology, physics.
[2] L. Gras,et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. , 1998, International journal of radiation oncology, biology, physics.
[3] M. Goitein,et al. Fitting of normal tissue tolerance data to an analytic function. , 1991, International journal of radiation oncology, biology, physics.
[4] G. Gustafson,et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. , 2005, International journal of radiation oncology, biology, physics.
[5] F Foppiano,et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[6] C. Fiorino,et al. Predictive models of toxicity with external radiotherapy for prostate cancer , 2009, Cancer.
[7] A B Wolbarst,et al. Optimization of radiation therapy, IV: A dose-volume histogram reduction algorithm. , 1989, International journal of radiation oncology, biology, physics.
[8] R. Valicenti,et al. Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer. , 2003, International journal of radiation oncology, biology, physics.
[9] Franca Foppiano,et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] A B Wolbarst,et al. Optimization of radiation therapy, III: A method of assessing complication probabilities from dose-volume histograms. , 1987, International journal of radiation oncology, biology, physics.
[11] Tom W J Scheenen,et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. , 2006, International journal of radiation oncology, biology, physics.
[12] M. V. van Herk,et al. Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): relationships with local dose, acute effects, and baseline characteristics. , 2010, International journal of radiation oncology, biology, physics.
[13] Manuela Gariboldi,et al. To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. , 2009, International journal of radiation oncology, biology, physics.
[14] Patrick A Kupelian,et al. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. , 2005, International journal of radiation oncology, biology, physics.
[15] C. Fiorino,et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. , 2008, International journal of radiation oncology, biology, physics.
[16] George Starkschall,et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. , 2002, International journal of radiation oncology, biology, physics.
[17] J. Lebesque,et al. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. , 2009, International journal of radiation oncology, biology, physics.
[18] M. Zelefsky,et al. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. , 1998, International journal of radiation oncology, biology, physics.
[19] G. Sanguineti,et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma , 2002, British Journal of Cancer.
[20] Richard K Valicenti,et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. , 2004, International journal of radiation oncology, biology, physics.
[21] V. Weinberg,et al. Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer. , 2001, Urology.
[22] Christopher A Peters,et al. Association of Single Nucleotide Polymorphisms in SOD2, XRCC1 and XRCC3 with Susceptibility for the Development of Adverse Effects Resulting from Radiotherapy for Prostate Cancer , 2008, Radiation research.
[23] R. Mohan,et al. Dose-volume response analyses of late rectal bleeding after radiotherapy for prostate cancer. , 2004, International journal of radiation oncology, biology, physics.
[24] Michael J. Zelefsky,et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. , 2002, International journal of radiation oncology, biology, physics.
[25] C. Ling,et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. , 2000, International journal of radiation oncology, biology, physics.
[26] Y. Yamada,et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[27] Lei Dong,et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[28] E. Yorke,et al. Use of normal tissue complication probability models in the clinic. , 2010, International journal of radiation oncology, biology, physics.
[29] A. Hanlon,et al. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. , 2004, International journal of radiation oncology, biology, physics.
[30] M. Goitein,et al. Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.
[31] D. Spelbring,et al. A method of analyzing rectal surface area irradiated and rectal complications in prostate conformal radiotherapy. , 1995, International journal of radiation oncology, biology, physics.
[32] Radhe Mohan,et al. Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer. , 2004, International journal of radiation oncology, biology, physics.
[33] C. Fiorino,et al. Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[34] A. Hanlon,et al. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. , 2004, International journal of radiation oncology, biology, physics.
[35] L. Incrocci,et al. Incidence, etiology, and therapy for erectile dysfunction after external beam radiotherapy for prostate cancer. , 2002, Urology.
[36] M. Keyes,et al. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. , 2004, International journal of radiation oncology, biology, physics.
[37] A. Hanlon,et al. Diabetes mellitus: a predictor for late radiation morbidity. , 1999, International journal of radiation oncology, biology, physics.
[38] M. Zelefsky,et al. Long term tolerance of high dose three‐dimensional conformal radiotherapy in patients with localized prostate carcinoma , 1999, Cancer.
[39] W. Butler,et al. A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy-induced erectile dysfunction. , 2000, International journal of radiation oncology, biology, physics.
[40] R. Mohan,et al. Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. , 2002, International journal of radiation oncology, biology, physics.
[41] Joseph O Deasy,et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. , 2010, International journal of radiation oncology, biology, physics.
[42] Joos V Lebesque,et al. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. , 2006, International journal of radiation oncology, biology, physics.
[43] R. Crevoisier,et al. Benefit of IMRT in High Dose Prostate Cancer Radiotherapy , 2010 .
[44] Sambasivarao Damaraju,et al. Association of DNA Repair and Steroid Metabolism Gene Polymorphisms with Clinical Late Toxicity in Patients Treated with Conformal Radiotherapy for Prostate Cancer , 2006, Clinical Cancer Research.
[45] Radiothérapie de conformation avec modulation d’intensité dans le cancer de prostate : vers un nouveau standard , 2009 .
[46] Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5-year minimum follow-up. , 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[47] Franca Foppiano,et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. , 2003, International journal of radiation oncology, biology, physics.
[48] Margie Hunt,et al. Intensity-modulated radiation therapy: supportive data for prostate cancer. , 2008, Seminars in radiation oncology.
[49] Steve Webb,et al. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[50] R. Pötter,et al. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[51] M. Zelefsky,et al. Dosimetric and anatomic indicators of late rectal toxicity after high-dose intensity modulated radiation therapy for prostate cancer. , 2008, Medical physics.
[52] D. Kuban,et al. Erectile dysfunction and radiation dose to penile base structures: a lack of correlation. , 2004, International journal of radiation oncology, biology, physics.
[53] A. Hanlon,et al. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. , 2005, International journal of radiation oncology, biology, physics.
[54] P. Fransson,et al. Prospective evaluation of urinary and intestinal side effects after BeamCath stereotactic dose-escalated radiotherapy of prostate cancer. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[55] C. De Wagter,et al. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[56] R. T. Ten Haken,et al. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[57] Gabor Fichtinger,et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study , 2007, Radiation oncology.
[58] S. Fosså,et al. Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy. , 1999, International journal of radiation oncology, biology, physics.
[59] Lei Dong,et al. Fit of a Generalized Lyman Normal-Tissue Complication Probability (NTCP) Model to Grade ≥ 2 Late Rectal Toxicity Data From Patients Treated on Protocol RTOG 94-06 , 2007 .
[60] C. Fiorino,et al. Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[61] Yoshiya Yamada,et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. , 2008, International journal of radiation oncology, biology, physics.
[62] R. Mohan,et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. , 1991, International journal of radiation oncology, biology, physics.
[63] Steve Webb,et al. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. , 2010, International journal of radiation oncology, biology, physics.
[64] L. Incrocci. Radiation therapy for prostate cancer and erectile (dys)function: The role of imaging , 2005, Acta oncologica.
[65] J. Fowler,et al. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison. , 2009, International journal of radiation oncology, biology, physics.
[66] Di Yan,et al. Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models. , 2007, International journal of radiation oncology, biology, physics.
[67] F. Saad,et al. Natural history and treatment of bone complications in prostate cancer. , 2006, European urology.
[68] R Mohan,et al. Clinically relevant optimization of 3-D conformal treatments. , 1992, Medical physics.
[69] J. Purdy,et al. Use of benchmark dose-volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer. , 2006, International journal of radiation oncology, biology, physics.
[70] Daniel W. Miller,et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.
[71] W. Lee,et al. Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapy. , 2002, Brachytherapy.
[72] P. Koper,et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. , 2005, International journal of radiation oncology, biology, physics.
[73] B. Dubray,et al. Probabilités de lésion des organes à risque : historique et principaux modèles mathématiques d’estimation , 2010 .
[74] G. Sanguineti,et al. Dose-volume effects for normal tissues in external radiotherapy: pelvis. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[75] M. Sydes,et al. Late Gastrointestinal Toxicity After Dose-Escalated Conformal Radiotherapy for Early Prostate Cancer: Results From the UK Medical Research Council RT01 Trial (ISRCTN47772397) , 2010, International journal of radiation oncology, biology, physics.
[76] J. Lyman. Complication Probability as Assessed from Dose-Volume Histograms , 1985 .
[77] Roberto Orecchia,et al. Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[78] Riccardo Calandrino,et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). , 2002, International journal of radiation oncology, biology, physics.
[79] D. Dearnaley,et al. Optimization of coplanar six-field techniques for conformal radiotherapy of the prostate. , 2000, International journal of radiation oncology, biology, physics.
[80] A Pollack,et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. , 2000, International journal of radiation oncology, biology, physics.
[81] A G Macdonald,et al. Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).
[82] R. Mohan,et al. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. , 2004, International journal of radiation oncology, biology, physics.
[83] G J Kutcher,et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. , 2001, International journal of radiation oncology, biology, physics.
[84] J. Lebesque,et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.
[85] J. Purdy,et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. , 2004, International journal of radiation oncology, biology, physics.